Tenaya Therapeutics to Present Preclinical Data on Its Gene Therapy Programs at the ESGCT 28th Annual Congress
October 12 2021 - 6:05PM
Business Wire
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnology company
with a mission to discover, develop and deliver curative therapies
that address the underlying causes of heart disease, announced
today that it will present new preclinical data at the virtual 28th
Annual Congress of the European Society of Gene and Cell Therapy
(ESGCT), October 19 - 22, 2021.
In an oral presentation, Tenaya will present key data on TN-201,
its AAV-based gene therapy product candidate for patients carrying
mutations of the MYBPC3 gene, the most common genetic cause of
hypertrophic cardiomyopathy (HCM) that affects more than 115,000
patients in the United States alone. TN-201 is in IND-enabling
studies, and Tenaya expects to file an IND in 2022.
Additionally, a late-breaker poster will be published on the
event website including the first preclinical data related to
Tenaya’s AAV-based gene therapy program for patients carrying
mutations of the PKP2 gene, the most common genetic cause of
arrhythmogenic right ventricular cardiomyopathy (ARVC) that affects
more than 70,000 patients in the United States alone. This program
is in the candidate selection stage.
Oral Presentation:
“Prevention of Premature Lethality and Reversal of Cardiac
Hypertrophy with an Optimized MYBPC3 Gene Therapy” Wednesday,
October 20, 2021, 10:45 a.m. – 11:00 a.m. ET (16:45 – 17:00 CEST)
(Session 3c) Laura Lombardi, Associate Director, Gene Therapy
Biology, Tenaya Therapeutics
Poster:
“Cardiac AAV:PKP2 Gene Transfer Prevents Development of
Arrhythmogenic Cardiomyopathy in a PKP2-deficient Mouse Model” This
poster will only be available on the ESGCT website on October 19,
2021.
To view full event programming, please visit the ESGCT
website.
About Tenaya Therapeutics Tenaya Therapeutics is a
biotechnology company committed to a bold mission: to discover,
develop and deliver curative therapies that address the underlying
drivers of heart disease. Founded by leading cardiovascular
scientists from Gladstone Institutes and the University of Texas
Southwestern Medical Center, Tenaya is developing therapies for
rare genetic disorders as well as for more prevalent heart
conditions through three distinct but interrelated product
platforms: Gene Therapy, Cellular Regeneration and Precision
Medicine. For more information, visit
www.tenayatherapeutics.com.
Forward-Looking Statements This press release contains
forward-looking statements as that term is defined in Section 27A
of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Statements in this press release that are not
purely historical are forward-looking statements. Words such as
“expects” and “will,” and similar expressions are intended to
identify forward-looking statements. Such forward-looking
statements include, among other things, Tenaya’s expectations
regarding the timing of the IND filing for TN-201. The
forward-looking statements contained herein are based upon Tenaya’s
current expectations and involve assumptions that may never
materialize or may prove to be incorrect. These forward-looking
statements are neither promises nor guarantees and are subject to a
variety of risks and uncertainties, including but not limited to:
risks associated with the process of discovering, developing and
commercializing drugs that are safe and effective for use as human
therapeutics and operating as an early stage company; Tenaya’s
ability to develop, initiate or complete preclinical studies and
clinical trials, and obtain approvals, for any of its product
candidates; the timing, progress and results of preclinical studies
for TN-201 and Tenaya’s other programs; Tenaya’s ability to raise
any additional funding it will need to continue to pursue its
business and product development plans; negative impacts of the
COVID-19 pandemic on Tenaya’s manufacturing and operations,
including preclinical studies and planned clinical trials; the
timing, scope and likelihood of regulatory filings and approvals;
the potential for any clinical trial results to differ from
preclinical, interim, preliminary, topline or expected results;
Tenaya’s manufacturing, commercialization and marketing
capabilities and strategy; the loss of key scientific or management
personnel; competition in the industry in which Tenaya operates;
Tenaya’s reliance on third parties; Tenaya’s ability to obtain and
maintain intellectual property protection for its product
candidates; general economic and market conditions; and other
risks. Information regarding the foregoing and additional risks may
be found in the section entitled “Risk Factors” in documents that
Tenaya files from time to time with the Securities and Exchange
Commission. These forward-looking statements are made as of the
date of this press release, and Tenaya assumes no obligation to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211012006197/en/
Investor Relations: Leone Patterson Tenaya Therapeutics
IR@tenayathera.com
Media: Wendy Ryan Ten Bridge Communications
wendy@tenbridgecommunications.com (781) 316-4424
Tenaya Therapeutics (NASDAQ:TNYA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Tenaya Therapeutics (NASDAQ:TNYA)
Historical Stock Chart
From Oct 2023 to Oct 2024